SSG
MDGL icon

Summit Securities Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Summit Securities Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$53K – 690
2024
Q1 		$53K Buy
+200
New +$47.1K 0.01% 248

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Summit Securities Group's MDGL Position: Q2 2025 in Review

Summit Securities Group sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 100 shares — an estimated $33.1K sold.

Summit Securities Group first reported a position in MDGL in Q2 2013 and held it in 3 quarters. The position peaked at $33.1K in Q1 2025. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Summit Securities Group reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 100 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $33.1K.
  • Summit Securities Group first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Summit Securities Group's Madrigal Pharmaceuticals position peaked at $33.1K in Q1 2025.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.